Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Rheumatology

Standard of Care: The Treatment Roadmap for IMNM

At a Glance

The standard of care for Immune-Mediated Necrotizing Myopathy (IMNM) requires early, aggressive combination therapy to prevent permanent muscle damage. Treatment usually begins with high-dose steroids paired with IVIG or immunosuppressants, followed by long-term maintenance to sustain remission.

Because Immune-Mediated Necrotizing Myopathy (IMNM) is an aggressive disease that causes rapid muscle death, the modern “standard of care” has shifted toward early, intensive, and often multi-drug therapy [1][2].

While steroids are highly effective for initial control to rapidly dampen the immune attack, they are usually insufficient to maintain long-term remission on their own. This makes IMNM “steroid-resistant” over time, meaning that most patients will need additional medications to stay in remission [3][4].

The First Line: Stopping the Attack

Treatment typically begins with high-dose corticosteroids (like prednisone) [5]. However, current guidelines frequently recommend adding a second medication immediately [2][3].

  • Intravenous Immunoglobulin (IVIG): This involves infusions of healthy antibodies from donors. IVIG is considered highly effective for IMNM and is often used early, especially for the anti-HMGCR subtype [5][6].
  • Steroid-Sparing Agents: To help reduce the dose of steroids over time, doctors often start “steroid-sparing” immunosuppressants like methotrexate, azathioprine, or mycophenolate mofetil [2][7].
  • Cancer Priority: For those who are seronegative or have unexpected presentations, ruling out underlying cancer must happen simultaneously with beginning these therapies [8].

Second Line and Refractory Cases

If the first-line combination does not sufficiently lower your Creatine Kinase (CK) levels or improve your strength within a few months, your doctor may escalate to “second-line” or “refractory” treatments [9][10].

  • Rituximab: This is a specialized medication that targets and removes the “B-cells” that produce the harmful autoantibodies. It is often used for patients with the anti-SRP subtype or those who do not respond to IVIG [11][12].
  • Tacrolimus: This is a potent immunosuppressant that can be added to combination therapy to help control the immune response [13][14].
  • Plasma Exchange (Plasmapheresis): In severe cases, doctors may use a machine to physically filter the harmful antibodies out of your blood [15][16].

The Reality of Side Effects

Aggressive immunosuppression is absolutely necessary to save your muscles, but it carries significant risks that you and your doctor must actively manage.

  • Infection Risk: Medications like rituximab, tacrolimus, and high-dose steroids severely lower your body’s ability to fight off routine viruses and bacteria [11]. You must be highly vigilant about infection prevention and report fevers immediately.
  • Metabolic Changes: High-dose steroids cause significant changes to your body, including weight gain, bone density loss (osteoporosis risk), and elevated blood sugar (steroid-induced diabetes) [5]. Your doctor should provide a structured plan for managing these side effects.

The Treatment Decision Tree

While every patient is unique, the typical progression of care follows this general logic:

Phase Common Medications Goal
Induction (First 1-3 Months) High-dose Steroids + IVIG or Methotrexate Stop active muscle death and lower CK levels [2].
Escalation (Months 3-6) Addition of Rituximab or Tacrolimus Achieve remission if first-line drugs aren’t enough [12].
Maintenance (Long-term) Low-dose Steroids + Methotrexate/Azathioprine Prevent relapses and maintain muscle strength [7].

The “Window of Opportunity”

The most critical factor in your long-term recovery is timing. Research consistently shows that starting aggressive treatment within the first few months of symptoms leads to better outcomes [17][1]. Delays in treatment can allow muscle fibers to be replaced by fat (atrophy), which is much harder to reverse [18]. Your goal, and your doctor’s goal, is to “turn off the fire” as quickly as possible [17].

Common questions in this guide

Why are steroids alone not enough to treat IMNM?
IMNM is an aggressive disease that often becomes steroid-resistant over time. Most patients require a combination of high-dose steroids and a second medication, like IVIG or methotrexate, to rapidly stop the immune attack and maintain long-term remission.
When is rituximab used for IMNM?
Rituximab is a specialized medication often used as a second-line therapy if initial treatments fail to lower Creatine Kinase (CK) levels. It is also frequently recommended early in the treatment plan for patients diagnosed with the anti-SRP subtype of IMNM.
How fast should I start treatment for IMNM?
Treatment should begin as quickly as possible, ideally within the first few months of symptom onset. This early window of opportunity is crucial to stop active muscle death before muscle fibers are permanently replaced by fat.
What is IVIG and how does it treat IMNM?
Intravenous Immunoglobulin (IVIG) is a therapy that delivers healthy donor antibodies directly into your bloodstream. It is highly effective at calming the immune system and is frequently used as a first-line treatment, especially for the anti-HMGCR subtype of IMNM.
What are the side effects of aggressive IMNM medications?
Strong immunosuppressants significantly increase your risk of routine infections. Additionally, high-dose steroids can cause major metabolic changes, such as weight gain, bone density loss, and steroid-induced diabetes, which require careful monitoring by your doctor.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given that IMNM often resists steroid monotherapy, should we start a second agent like methotrexate or IVIG immediately?
  2. 2.If I have the anti-SRP subtype, should we consider adding rituximab early in my treatment plan?
  3. 3.What is our target goal for my CK levels, and how soon should we expect to see them start dropping?
  4. 4.If my symptoms do not improve within the first month, what is the 'escalation plan' for my treatment?
  5. 5.Are we monitoring for the side effects of high-dose steroids, and is there a plan for a 'steroid-sparing' long-term strategy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Statin-Related Necrotizing Autoimmune Myositis: More Than Myalgia.

    Scheuing WJ, Dadhania FB, Bankole AA

    Cureus 2022; (14(2)):e22654 doi:10.7759/cureus.22654.

    PMID: 35371630
  2. 2

    Immune-Mediated Necrotizing Myopathy: A Systematic Review of Antibody-Specific Mechanisms and Treatment Outcomes.

    Vaezi Z, Amini A

    Cureus 2025; (17(11)):e97933 doi:10.7759/cureus.97933.

    PMID: 41458822
  3. 3

    Immune-Mediated Necrotizing Myopathy.

    Pinal-Fernandez I, Casal-Dominguez M, Mammen AL

    Current rheumatology reports 2018; (20(4)):21 doi:10.1007/s11926-018-0732-6.

    PMID: 29582188
  4. 4

    Immune-mediated necrotizing myopathy: clinical features and pathogenesis.

    Allenbach Y, Benveniste O, Stenzel W, Boyer O

    Nature reviews. Rheumatology 2020; (16(12)):689-701 doi:10.1038/s41584-020-00515-9.

    PMID: 33093664
  5. 5

    Autoimmune Myopathies: Updates on Evaluation and Treatment.

    McGrath ER, Doughty CT, Amato AA

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2018; (15(4)):976-994 doi:10.1007/s13311-018-00676-2.

    PMID: 30341597
  6. 6

    Outcome predictors of immune-mediated necrotizing myopathy-a retrospective, multicentre study.

    Wang JX, Wilkinson M, Oldmeadow C, et al.

    Rheumatology (Oxford, England) 2022; (61(9)):3824-3829 doi:10.1093/rheumatology/keac014.

    PMID: 35022671
  7. 7

    Challenges in the diagnosis and management of immune-mediated necrotising myopathy (IMNM) in a patient on long-term statins.

    Khan F, Brady S, Kuttikat A

    Rheumatology international 2023; (43(2)):383-390 doi:10.1007/s00296-022-05230-0.

    PMID: 36260115
  8. 8

    Paraneoplastic anti-SRP antibody positive immune-mediated necrotizing myopathy in a young female associated with lymphoma.

    Heugenhauser J, Pauli FD, Stockhammer G, et al.

    Journal of neuromuscular diseases 2025; (12(4)):567-574 doi:10.1177/22143602251327002.

    PMID: 40266663
  9. 9

    Statin-Associated Autoimmune Myopathy: Review of the Literature.

    Barrons R

    Journal of pharmacy practice 2023; (36(2)):383-393 doi:10.1177/08971900211040291.

    PMID: 35707933
  10. 10

    Autoantibody-Negative Immune-Mediated Necrotizing Myopathy Responds to Early and Aggressive Treatment: A Case Report.

    Marotta DA, Zadourian A, Jabaay MJ, et al.

    Cureus 2020; (12(4)):e7827 doi:10.7759/cureus.7827.

    PMID: 32467802
  11. 11

    Statin-induced anti-HMGCR antibody-related immune-mediated necrotising myositis achieving complete remission with rituximab.

    Zhang W, Prince HM, Reardon K

    BMJ case reports 2019; (12(11)) doi:10.1136/bcr-2019-232406.

    PMID: 31791994
  12. 12

    Rheumatoid Arthritis Associated With Anti-Signal Recognition Particle Immune-Mediated Necrotizing Myopathy: A Case Report.

    Belkhribchia MR, Lobrinus JA, Semlil L, et al.

    Journal of investigative medicine high impact case reports 2024; (12()):23247096241231646 doi:10.1177/23247096241231646.

    PMID: 38353222
  13. 13

    Evaluation of the effectiveness of using prednisolone, tacrolimus, and intravenous immunoglobulin combination therapy on immune-mediated necrotizing myopathy-A non-randomized, observational research.

    Liu M, Liu J, Li K, et al.

    International journal of rheumatic diseases 2024; (27(3)):e15124 doi:10.1111/1756-185X.15124.

    PMID: 38514893
  14. 14

    A Rare Case of Statin-induced Immune-mediated Necrotizing Myopathy.

    Madgula AS, Gadela NV, Singh M, Chen K

    Cureus 2020; (12(4)):e7500 doi:10.7759/cureus.7500.

    PMID: 32373404
  15. 15

    Therapeutic plasma exchange for the treatment of refractory necrotizing autoimmune myopathy.

    Kruse RL, Albayda J, Vozniak SO, et al.

    Journal of clinical apheresis 2022; (37(3)):253-262 doi:10.1002/jca.21968.

    PMID: 35119135
  16. 16

    Plasma Exchange in Anti-Signal Recognition Particle Myopathy: A Systematic Review and Combined Analysis of Patient Individual Data.

    Martínez-Rodríguez P, Escribano-Iglesias M, Crisolino-Pozas ÁP, et al.

    Journal of personalized medicine 2024; (14(5)) doi:10.3390/jpm14050461.

    PMID: 38793043
  17. 17

    Clinical Characteristics and Management of Statin-Associated Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Immune-Mediated Necrotizing Myopathy.

    Yoon J, Kim SW, Kim SH, et al.

    Journal of clinical medicine 2025; (14(18)) doi:10.3390/jcm14186610.

    PMID: 41010829
  18. 18

    Whole-body MRI and pathological findings in adult patients with myopathies.

    Tomas X, Milisenda JC, Garcia-Diez AI, et al.

    Skeletal radiology 2019; (48(5)):653-676 doi:10.1007/s00256-018-3107-1.

    PMID: 30377729

This page provides educational information on the standard treatment timeline and medications for IMNM. Always consult your rheumatologist or neurologist before making any decisions about your treatment plan.

Get notified when new evidence is published on Immune-mediated necrotizing myopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.